The global fight against emerging infectious diseases received a significant boost this month with a landmark licensing agreement between the University of Oxford and the Serum Institute of India (SII). The collaboration aims to accelerate the development and manufacturing of a vaccine against Nipah virus, a highly lethal zoonotic pathogen that poses a growing threat to public health in South and Southeast Asia. This partnership is particularly crucial given the current lack of approved vaccines to prevent Nipah virus infection, a gap that has spurred urgent research efforts worldwide.
The SII, the world’s largest vaccine manufacturer, has secured a non-exclusive, worldwide license to develop, manufacture, and potentially supply the ChAdOx1 NipahB vaccine candidate, developed by researchers at the University of Oxford. This agreement, announced on March 13, 2026, builds upon promising preclinical results and the initiation of a Phase 2a clinical trial to evaluate the vaccine’s safety and immunogenicity in humans. The urgency surrounding Nipah virus stems from its high mortality rate – ranging from 40% to 75% – and its potential to cause widespread outbreaks, as highlighted by the World Health Organization (WHO), which lists Nipah virus as a priority pathogen with pandemic potential. Oxford University News details the agreement.
A Collaborative Approach to Nipah Virus Vaccine Development
The ChAdOx1 NipahB vaccine candidate utilizes the same viral vector platform – ChAdOx1 – that underpinned the development of the Oxford-AstraZeneca COVID-19 vaccine. This technology, known for its rapid development and scalability, offers a significant advantage in responding to emerging infectious disease threats. The development of the vaccine is being funded by the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership working to accelerate the development of vaccines against emerging infectious diseases. CEPI’s support has been instrumental in advancing the vaccine candidate through preclinical studies, which demonstrated strong immune responses and protection against infection in animal models. CEPI’s announcement provides further details on the trial’s progress.
The licensing agreement with the SII is a critical step towards ensuring global access to a potential Nipah virus vaccine. The SII’s extensive manufacturing capacity and established distribution networks will be essential for producing and delivering the vaccine to regions most at risk. Dr. Umesh Shaligram, CEO of the Serum Institute of India, emphasized the company’s commitment to supporting the clinical development and global preparedness efforts against Nipah virus, leveraging their experience with the ChAdOx1 platform. The SII’s capabilities are particularly important given the logistical challenges associated with responding to outbreaks in remote and resource-limited settings.
Understanding the Nipah Virus Threat
Nipah virus is a zoonotic virus, meaning it originates in animals and can be transmitted to humans. The natural reservoir for the virus is fruit bats, primarily Pteropus species. Human infections typically occur through consumption of contaminated date palm sap or direct contact with infected animals, such as pigs. Human-to-human transmission is also possible, particularly in healthcare settings, making outbreaks particularly challenging to control. The virus was first identified in Malaysia in 1999, following an outbreak among pig farmers, and has since caused outbreaks in Bangladesh, India, and the Philippines. The Serum Institute of India highlights the importance of preparedness.
Symptoms of Nipah virus infection can range from mild respiratory illness to severe encephalitis (inflammation of the brain) and acute respiratory distress syndrome. Initial symptoms often include fever, headache, muscle pain, vomiting, and sore throat. However, the disease can rapidly progress to more severe neurological complications, leading to seizures, coma, and death. The high mortality rate and the potential for rapid spread make Nipah virus a significant public health concern, particularly in regions where outbreaks are common. The WHO emphasizes the need for enhanced surveillance, early detection, and rapid response measures to control outbreaks and prevent further transmission.
Clinical Trial Progress and Regulatory Pathways
Currently, a Phase 2a clinical trial is underway to assess the safety and immunogenicity of the ChAdOx1 NipahB vaccine in humans. This trial, initiated earlier this month, is being conducted in Bangladesh, a country that experiences recurrent Nipah virus outbreaks. The trial will enroll 306 healthy adults aged 18 to 55 and will provide crucial data on the vaccine’s ability to elicit an immune response and its safety profile. The results of this trial are expected to inform the design of larger Phase 2b trials, which will be conducted in regions where Nipah virus outbreaks occur.
Regulatory pathways for the vaccine are expected to be based on a combination of clinical data, immunogenicity data, preclinical evidence, and responses observed during outbreaks. Given the sporadic and limited nature of Nipah virus outbreaks, traditional efficacy trials may be challenging to conduct. Regulators are likely to consider a flexible approach, incorporating data from multiple sources to assess the vaccine’s potential effectiveness. Oxford University Innovation (OUI) has played a key role in facilitating the licensing agreement between Oxford and the SII, recognizing the importance of translating promising research into tangible solutions for global health challenges.
Preparing for Future Outbreaks
In addition to the ongoing clinical trials, efforts are underway to establish a global reserve of Nipah virus vaccines. CEPI, the SII, and the University of Oxford are collaborating to manufacture up to 100,000 doses of the ChAdOx1 NipahB vaccine for investigational use during future outbreaks. These reserve doses could be deployed rapidly under emergency use authorization to control outbreaks, generate critical data, and potentially halt epidemics in their tracks. This proactive approach to vaccine preparedness is essential for mitigating the impact of Nipah virus and protecting vulnerable populations.
Professor Brian Angus, a professor of internal medicine at the University of Oxford and leader of the university’s vaccine group, underscored the constant threat posed by Nipah virus to communities in Asia. He stated, “Our goal is to transform scientific discoveries into vaccines that support prevent future outbreaks and save lives.” This sentiment reflects the broader commitment of the scientific community to developing effective countermeasures against emerging infectious diseases and strengthening global health security. The collaboration between Oxford, the SII, and CEPI represents a significant step forward in this ongoing effort.
The development of a Nipah virus vaccine is not merely a scientific achievement; It’s a testament to the power of international collaboration and the unwavering commitment to protecting global health. As the world continues to grapple with the threat of emerging infectious diseases, partnerships like this one will be crucial for ensuring that effective vaccines and treatments are available to those who need them most. The ongoing Phase 2a trial and the establishment of a global vaccine reserve offer a glimmer of hope in the fight against this deadly virus.
The next key milestone will be the release of preliminary data from the Phase 2a clinical trial in Bangladesh, anticipated in late 2026 or early 2027. These results will be critical for informing the future development and deployment of the ChAdOx1 NipahB vaccine. We encourage readers to share this article and engage in discussions about the importance of pandemic preparedness and global health security.